Tirzepatide denied as duplicate or overlapping therapy by Anthem?

Anthem's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied Tirzepatide as Duplicate Therapy

Anthem's duplicate-therapy denial reflects a determination by the plan that another medication already active on your pharmacy record is therapeutically equivalent to tirzepatide — making the new prescription redundant in the plan's view. This commonly occurs when a prior GLP-1 receptor agonist or another agent for diabetes or weight management is still listed as active, even if your prescriber intends tirzepatide to serve as a direct replacement.

This denial is appealable because tirzepatide has a mechanism distinct from other agents in its broader therapeutic category, and your prescriber can provide clinical documentation explaining why the prior agent is being discontinued and why tirzepatide — rather than continuation of the existing therapy — is medically necessary for your individual clinical situation.

## Your Appeal Rights

• ACA §2719 / ERISA §503: Federal law requires non-grandfathered plans to provide a full-and-fair internal review process and independent external review if the internal appeal fails.
• Internal appeal deadline: Typically 180 days from the date on your denial or Explanation of Benefits; verify the exact date on your notice from Anthem.
• External review window: Approximately four months from a final internal denial to file for independent external review by an accredited review organization.
• Expedited review: If the clinical situation is urgent, you may request expedited internal and external review simultaneously; decisions are required on accelerated federal timelines.

## Documentation to Gather

1. Transition documentation: A clear record — including dates — showing the prior overlapping therapy is being stopped or was already discontinued, with the clinical rationale documented in your chart. 2. Diagnosis confirmation: Current visit notes or clinical records confirming your diagnosis (e.g., type 2 diabetes, obesity, or both) and its severity. 3. Prior therapy history with dates and outcomes: A chronological account of prior agents, documenting the duration of use and the specific clinical reason each was not continued — inadequate response, side effects, prescriber clinical judgment. 4. Prescriber medical-necessity letter: A letter from your treating physician or advanced practitioner addressing Anthem's duplicate-therapy determination directly. The letter should explain the clinical distinction between tirzepatide and the prior agent and state why the switch is medically necessary rather than duplicative. 5. Insurer policy mapping: Obtain Anthem's current published coverage or clinical policy for tirzepatide. Address each requirement listed, with a direct chart citation for each, to show your case meets all applicable criteria.

## Criteria-Mapping Structure

Build your appeal submission around a structured rebuttal: Anthem's basis for duplicate classification (quoted from the denial) | Clinical distinction or transition evidence | Chart or document reference. If the plan's system simply has not yet registered the discontinuation of the prior agent, a pharmacy or prescriber attestation of that discontinuation — with a date — can often resolve the denial quickly at the internal review stage.

Verify the current FDA-approved indications in tirzepatide's official prescribing information and review Anthem's most current published clinical policy before submitting your appeal.